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ABSTRACT 
Tribbles pseudokinase 3 (TRIB3) has been proposed to act as an inhibitor of AKT 
although the precise molecular bases of this activity and whether loss of TRIB3 
contributes to cancer initiation and progression remain to be clarified. In this study, by 
using a wide array of in vitro and in vivo approaches, including a Trib3 knock-out 
mouse, we demonstrate that TRIB3 plays a tumor-suppressing role. We also find that 
the mechanism by which TRIB3 loss enhances tumorigenesis relies on the dys-
regulation of the phosphorylation of AKT by the mTORC2 complex, which leads to an 
enhanced phosphorylation of AKT on Ser473 and the subsequent hyper-
phosphorylation and inactivation of the transcription factor FOXO3. These observations 
support the notion that loss of TRIB3 is associated with a more aggressive phenotype in 
various types of tumors by enhancing the activity of the mTORC2/AKT/FOXO axis. 
 
Keywords: AKT pathway; cancer; cell signalling; pseudokinases.
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INTRODUCTION 
Pseudokinases constitute a group of proteins that have a kinase-like domain that lacks at 
least one of the conserved catalytic residues (1, 2). Different studies have shown that 
some pseudokinases can exhibit low levels of kinase activity, while others play critical 
roles as activators of their specific targets (1, 2). Moreover, aberrant regulation of 
pseudokinases has been implicated in the etiology and progression of a variety of 
diseases, including cancer (3). 
The Tribbles family of pseudokinases was first described in Drosophila as a 
negative regulator of cell division in early embryogenesis (4-7). There are three 
mammalian Tribbles isoforms (Trib1, Trib2 and Trib3), homologues to the Drosophila 
tribbles proteins, and they all share a highly conserved central kinase-like domain, 
which lacks catalytic residues, and a “tribbles specific” C-terminal domain, which has 
been proposed to participate in the binding to different Tribbles partners (8) .  
Tribbles pseudokinase-3 (TRIB3; also named TRB3, NIPK and SKIP3) has been 
proposed to interact with several proteins, including the transcription factors ATF4 and 
CHOP (9) as well as with several MAPKs (10). TRIB3 has also been shown to interact 
and inhibit AKT (11), which has been suggested to suppress insulin signaling (11, 12). 
In addition, administration of different anticancer agents promotes cancer cell death via 
TRIB3 up-regulation and the subsequent inhibition of Akt (13-19). However, the 
precise molecular bases of the regulation of Akt by TRIB3 and whether loss of this 
pseudokinase may contribute to cancer initiation and progression remains to be 
clarified. 
In this study we investigated the effect of the genetic inactivation of TRIB3 in 
several cellular and animal models of cancer. Our findings indicate that genetic 
inhibition of TRIB3 enhances tumorigenesis and that this effect is due - at least 
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primarily - to a selective inactivation of the transcription factor FOXO by the 
mTORC2/AKT axis. 
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RESULTS 
Genetic inhibition of TRIB3 facilitates oncogene transformation and enhances the 
tumorigenicity of cancer cells 
As a first approach to analyze the role of TRIB3 in cancer generation and progression, 
we investigated the susceptibility to transformation of mouse embryonic fibroblasts 
(MEFs) derived from Trib3-/- and wild type (WT) animals (see Experimental Procedures 
section and Supplementary Figure S1a-e). Expression of RasV12 (a constitutively active 
form of the oncogene Ras) was capable of transforming MEFs derived from Trib3 
deficient mice (Figure 1a). Similar results were obtained when the SV40 T-large antigen 
was used (Supplementary Figure S1f), suggesting that loss of TRIB3 facilitates 
oncogene-induced transformation overall. In line with this idea, a higher number of 
Trib3-deficient RasV12-transformed (Figure 1b) and SV40-T large antigen-transformed 
(Supplementary Figure S1g) MEFs were obtained after several days in culture when 
compared with their corresponding WT counterparts.  
Next, we generated RasV12/E1A-transformed MEFs as a cellular model to 
conduct additional mechanistic studies on the role of TRIB3 in cancer. In line with the 
aforementioned results, a higher percentage of RasV12/E1A-transformed Trib3-deficient 
MEFs were positive for Ki67, a marker expressed specifically in dividing cells, when 
compared with their corresponding WT counterparts (Figure 1c). Likewise, 
RasV12/E1A-transformed Trib3-/- MEFs formed four times the number of colonies in soft 
agar (Figure 1d) as their corresponding WT MEFs. Moreover, this behavior was 
abolished by re-expressing an HA-tagged form of TRIB3 in Trib3-deficient cells 
(Figure 1c and 1d), which strongly supports that the enhanced tumorigenic features of 
Trib3-deficient cells rely solely on the inactivation of this pseudokinase. Furthermore, 
the onset of tumor xenografts generated by subcutaneous injection of Trib3-deficient 
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RasV12/E1A-transformed MEFs in the flank of nude mice was remarkably accelerated 
compared to that of tumors generated with their WT counterparts (Figure 1e). 
Of note, TRIB3 is focally deleted in tumors of epithelial origin and in breast 
cancer patients (tumourscape dataset; Supplementary Table SI). In addition, analysis of 
gene expression profiles of cancer patients from published studies reveals that TRIB3 
mRNA levels are down-regulated in different tumor types (Supplementary Table SII 
and SIII). Therefore, we next investigated the effect of the genetic inhibition of TRIB3 
in human cancer cell lines. In line with the results obtained with Trib3-deficient MEFs, 
knock-down of TRIB3 strongly enhanced the ability to form colonies in soft agar of 
breast carcinoma (BT474) and hepatocellular carcinoma (HepG2) cells lines (Figure 
2a). Moreover, TRIB3 silencing increased the number of BT474 and HepG2 cells 
obtained after several days in culture (Supplementary Figure S2a-b). Furthermore, 
stable silencing of TRIB3 both accelerated tumor onset and enhanced the rate of tumor 
growth of xenografts generated with BT474 cells (Figure 2b), and accelerated the onset 
of HepG2 cell-generated tumors (Figure 2c). Taken together, these observations 
strongly support that loss of TRIB3 enhances the tumorigenic capacity of different types 
of cancer cells.  
 
Genetic deletion of Trib3 accelerates the progression of mouse skin papillomas to a 
more aggressive phenotype 
As a first approach to investigate the role of TRIB3 in the control of cancer progression, 
we analyzed the expression of this pseudokinase in several mouse skin carcinoma cell 
lines exhibiting different degrees of differentiation and aggressiveness. Specifically, we 
studied the expression of Trib3 in the MSC11B9/MSC11A5 and CarC-R/CarC cell 
lines, as they constitute homogenous cellular systems of malignant progression 
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[MSC11B9 and MSC11A5 cells were derived, respectively, from the squamous 
component and the more undifferentiated region of the same carcinoma (20); and CarC-
R is a minority population of less aggressive epithelial cells isolated from the 
fusocellular carcinoma cell line CarC (21).] Trib3 expression was much lower in 
MSC11A5 and CarC cells than in their corresponding more differentiated counterparts 
(Figure 3a). Likewise, Trib3 levels were lower in the spindle cell carcinoma cell line 
CarB when compared with those of PDV cells (derived from a squamous cell carcinoma 
cell line) (Figure 3a). Moreover, comparison of Trib3 mRNA levels of normal skin, 
papillomas and skin carcinomas from mice revealed that Trib3 expression correlated 
inversely with the aggressiveness of the lesion (Figure 3b). These observations support 
that down-regulation of Trib3 expression is associated with a more aggressive 
phenotype in mouse epithelial skin carcinomas. 
Based on these observations, we therefore next investigated the effect of Trib3 
genetic inactivation on the progression of the lesions observed in mice subjected to the 
two-stage skin carcinogenesis model as this is one of the best established paradigms for 
studying the mechanisms underlying malignant transformation in vivo (22). Skin tumors 
were induced in Trib3+/+  and Trib3-/- mice of a mixed C57BL6/J 129/Ola background 
(see Experimental procedures for details) by topical treatment with a single dose of 
7,12-dimethylbenz[a]anthracene (DMBA) followed by a repeated administration of the 
phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) for 20 weeks. After 
DMBA/TPA challenge, we observed no differences between Trib3+/+ and Trib3-/- mice 
either in the latency (time from treatment initiation to tumor development) or the size 
(data not shown) of the skin lesions. However, the frequency of malignant conversion, 
as determined by the percentage of papillomas that progressed into a more aggressive 
phenotype [squamous papillomas or squamous papillomas with dysplasia] was 
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significantly higher in Trib3-/- mice than in their corresponding WT littermates after 20 
or 32 weeks of the initiation of the treatment (Figure 3c and 3d). Statistically significant 
differences were not found between Trib3+/+ and Trib3-/- mice in the frequency of “in 
situ” or squamous cell carcinomas (Supplementary Figure S3). 
 
Loss of TRIB3 enhances the phosphorylation of AKT in cancer cells via mTORC2 
TRIB3 has been shown to interact with and inhibit AKT, and dysregulation of this 
kinase plays a crucial role in cancer generation and progression (23). Therefore, we next 
investigated whether the enhanced tumorigenic properties of cells in which TRIB3 has 
been genetically inhibited rely on an enhanced stimulation of the AKT signalling 
pathway. In line with this idea, RasV12/E1A-transformed Trib3-deficient MEFs, as well 
as breast carcinoma (BT474) and hepatocellular carcinoma (HepG2) cell lines in which 
TRIB3 had been knocked-down, exhibited an enhanced phosphorylation of AKT 
(Figure 4a and Supplementary Figure S4a). Moreover, the increase triggered by the 
genetic inhibition of Trib3 in the number of HepG2 andBT474 cells observed after 
several days in culture was prevented by the pharmacological inhibition of the Akt 
pathway (Supplementary Figure S4b-c). Likewise, knock-down of TRIB3 enhanced 
AKT phosphorylation in BT474-, HepG2- and U87MG-cell derived tumor xenografts 
(Figure 4b). Moreover, tumors derived from RasV12/E1A-transformed Trib3-/- cells 
exhibited higher phosphorylation levels of AKT than those derived from their 
corresponding WT counterparts (Figure 4b). Furthermore, cutaneous squamous 
papillomas from Trib3-/- mice also showed higher AKT phosphorylation levels than the 
papillomas derived from their WT littermates (Figure 4c).  
To investigate the mechanism by which the loss of TRIB3 enhances AKT 
phosphorylation we analyzed the effect of re-expressing an HA-tagged form of TRIB3 
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in TRIB3-deficient cells. TRIB3 re-expression abolished the enhanced phosphorylation 
of AKT in Ser 473 but did not modify the phosphorylation of the kinase in Thr 308 
(Figure 4d). Since AKT is phosphorylated on Ser473 by the mammalian target of 
rapamycin complex 2 (mTORC2) (24), we next investigated whether the enhanced 
phosphorylation of AKT on Ser 473 observed in Trib3-deficient cells relied on the 
dysregulation of the phosphorylation of AKT by mTORC2. In line with this idea, 
silencing of the mTORC2 protein component RICTOR or incubation with the mTOR 
kinase inhibitor torin-1 abolished the enhanced phosphorylation of AKT observed in 
RasV12/E1A-transformed Trib3-/- MEFs (Figure 4e) as it also did the re-expression of 
HA-TRIB3 (Supplementary Figure S4d). Moreover, Rictor knock-down prevented the 
increase (triggered by the genetic inhibition of Trib3) in the number (Figure 4f) and 
clonogenicity (Figure 4g) of RasV12/E1A-transformed MEFs, thus suggesting that the 
tumorigenic properties of Trib3-deficient cells rely on the enhanced phosphorylation of 
AKT by mTORC2. 
 
Loss of Trib3 enhances the incidence of premalignant and malignant lesions in 
Pten
+/-
 mice 
To investigate the relevance of the TRIB3-dependent regulation of AKT in cancer we 
next analyzed the in vivo effect of the genetic inactivation of Trib3 together with that of 
the tumor suppressor gene phosphatase and tensin homolog (PTEN). PTEN is a highly 
mutated and frequently lost tumor suppressor in cancer, that negatively regulates the 
activation of the PI3K pathway through the dephosphorylation of phosphatidylinositol 
3,4,5 trisphosphate (PIP3) (25). Importantly, studies in mice have demonstrated that 
PTEN is a haplo-insufficient tumor suppressor, as genetic deletion of one copy of the 
gene is sufficient to unleash oncogenic responses in different organs (26). Accordingly, 
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Pten
+/- mice exhibit an enhanced activation of the AKT pathway and spontaneously 
develop malignant lesions in different tissues, including prostate, adrenal glands and 
thyroid (27). Therefore, we crossed Trib3-/- mice with Pten+/- mice to study whether loss 
of Trib3 results in an acceleration of these lesions. Eight-month-old animals were 
sacrificed and histopathological analyses were performed to analyze the presence of 
pre-malignant and malignant lesions in different tissues. Trib3-/- mice exhibited a very 
low frequency of lesions in the different tissues analyzed. However, Pten+/- Trib3+/- and 
Pten
+/- 
Trib3
-/- mice showed a higher frequency of pre-malignant and malignant lesions 
than Pten+/- mice in prostate, adrenal glands and thyroid (Table I, Figure 5a and 
Supplementary Figure S5). Specifically, 100% of Pten+/- Trib3-/- vs. 50% of Pten+/- mice 
developed prostatic intraepithelial neoplasia (PIN). Likewise, 67% of Pten+/- Trib3-/- vs. 
37% of Pten+/- mice showed hyperplasia of the adrenal glands, and 11% of Pten+/- Trib3-
/- vs. 0% of Pten+/- mice developed pheochromocytomas (Figure 5a). Moreover, AKT 
phosphorylation was increased in hyperplasic adrenal medullas of Trib3-/- Pten+/- 
animals when compared with the same lesion in Pten+/- mice (Figure 5b). These 
findings strongly support that loss of Trib3 accelerates the formation of premalignant 
and malignant lesions in Pten+/- mice.  
 
Loss of Trib3 promotes FOXO inactivation 
Next, we investigated the targets of AKT that are involved in the enhanced tumorigenic 
features of cells in which TRIB3 has been genetically inhibited. Remarkably, genetic 
inhibition of Trib3 led to an enhanced phosphorylation of some of the downstream 
targets of AKT - namely the transcription factor Forkhead box O3 (FOXO3) and the 
BH3-only protein BCL2-associated agonist of cell death (BAD) - but not of others such 
as glycogen synthase kinase 3 (GSK3), or proline rich AKT substrate (PRAS40) (Figure 
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6a and Supplementary Figure S6a). Likewise, phosphorylation of FOXO3 (but not of 
the ribosomal protein S6 - whose phosphorylation correlates under many cellular 
settings with activation of the mTORC1 complex) was enhanced in TRIB3-silenced 
BT474 and HepG2, cells (Supplementary Figure S6b).  
We therefore next investigated whether the enhanced phosphorylation of 
FOXO3 and BAD observed in TRIB3-deficient cells relied on the dysregulation of the 
phosphorylation of AKT by mTORC2. In line with this idea, silencing of the mTORC2 
protein component Rictor or incubation with the mTOR kinase inhibitor torin-1 
abolished the enhanced phosphorylation of FOXO and BAD observed in Trib3-deficient 
MEFs at the same extent as the re-expression of HA-TRIB3. By contrast, 
phosphorylation of Pras40 was not modified in any of those experimental conditions 
(Figure 6b and Supplementary Figure S6c and S6d).  
It has been widely reported that the FOXO family of transcription factors plays 
an important tumor-suppressing role (28). Since genetic inhibition of Trib3 enhances 
FOXO3 phosphorylation - an event that typically leads to the inactivation and the 
subsequent sequestration in the cytosol of this transcription factor (23), (29, 30)- we 
asked whether the activity of FOXO is altered in Trib3-/- cells. In line with this idea, 
FOXO3 exhibited a primarily cytosolic localization in RasV12/E1A-transformed Trib3-/- 
MEFs subjected to serum withdrawal - an insult that typically leads to FOXO3 
translocation to the nucleus (30) (Figure 6c). In contrast, the distribution of FOXO3 was 
mainly nuclear in RasV12/E1A-transformed Trib3+/+ MEFs upon the same experimental 
conditions (Figure 6c). Likewise, serum withdrawal – which triggers the up-regulation 
of the Bcl-2 family gene Bcl-2 interacting mediator of cell death (BIM) in a FOXO-
dependent manner – led to the activation of the Bim promoter in Trib3+/+ but not in 
Trib3
-/- cells (Supplementary Figure S6e). Furthermore, TRIB3 re-expression restored 
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the ability of serum deprivation to activate the Bim promoter in Trib3-/- cells, and this 
effect was abolished when the FOXO binding sites were mutated in this promoter, thus 
supporting that TRIB3 participates in the regulation of FOXO activity (Figure 6d). To 
investigate the in vivo relevance of our findings we next analyzed whether genetic 
inhibition of TRIB3 affects the phosphorylation of FOXO in tumor samples. Knock-
down of TRIB3 enhanced FOXO3 phosphorylation in HepG2- andBT474- -cell derived 
tumor xenografts (Figure 6e) which occurred in concert with  an enhanced expression of 
a the cell  proliferation marker Ki67 in those tumors (Supplementary Figure S6f, and 
S6g). Likewise, tumors derived from RasV12/E1A-transformed Trib3-/- cells exhibited a 
higher phosphorylation of FOXO (Figure 6e) which was associated with an enhanced 
Ki67 immunostaining (Supplementary Figure S6h) compared to tumors derived from 
their corresponding WT counterparts. Furthermore, cutaneous squamous papillomas 
from Trib3-/- mice also showed higher FOXO1/3 phosphorylation levels than the 
papillomas derived from their WT littermates (Figure 6f).  
 
Loss of Trib3 enhances tumor growth via FOXO inactivation  
To study whether the enhanced tumorigenic properties of Trib3-/- cells relies on FOXO 
inhibition, we made use of a construct encoding a form of FOXO3 in which the residues 
phosphorylated by AKT are mutated to Ala (FOXO-A3). Unlike the endogenous form 
of FOXO3, the FOXO-A3 mutant locates in the nucleus of Trib3-/- cells (Figure 7a). 
Moreover, expression of FOXO-A3 in Trib3-/- cells re-established the pattern of FOXO–
regulated genes (Supplementary Figure S7a), as well as the ability of serum deprivation 
to activate the Bim promoter (Supplementary Figure S7b). In addition, FOXO-A3 
expression abolished the increase in the number of cells and the enhanced clonogenicity 
characteristic of Trib3-/- cells (Figure 7b and 7c).  
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Therefore, we next analyzed the effect of the stable expression of the FOXO-A3 
mutant on the ability of RasV12/E1A-transformed Trib3-/- MEFs to generate tumor 
xenografts. As shown in Figure 7d, the growth rate of tumors generated with Foxo-A3-
Trib3
-/- cells was strongly reduced in comparison with that of Trib3-/- cells. Likewise, 
tumors derived from FOXO-A3-Trib3-/- cells exhibited a decreased expression of Ki67 
when compared to those generated with Trib3-/- cells (Figure 7e). Taken together, these 
observations strongly support that the enhanced tumorigenic properties of Trib3-
deficient cells rely - at least in major part - on the enhanced phosphorylation and 
subsequent inhibition of FOXO transcription factors. 
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DISCUSSION 
Several observations presented in this work show that TRIB3 plays a remarkable tumor 
suppressive role. For example, (i) oncogenic transformation is facilitated in MEFs 
derived from Trib3-deficient mice; (ii) genetic inhibition of TRIB3 enhances 
proliferation, clonogenicity and the ability to generate tumor xenografts of oncogene-
transformed MEFs and of several human cancer cell lines; (iii) loss of TRIB3 enhances 
the frequency of malignant conversion of papillomas generated in mice subjected to 
DMBA/TPA treatment; and (iv) loss of TRIB3 enhances the incidence of premalignant 
and malignant lesions in Pten+/- mice.  
Our findings demonstrate that the tumor inhibitory role of TRIB3 relies to a 
large extent on the ability of this pseudokinase to regulate the activity of the AKT 
pathway. In line with this idea, we found that the genetic inactivation of Trib3 enhances 
the effect of the deletion of one of the two copies of Pten on the formation of pre-
malignant and malignant lesions in mice. Of note, AKT phosphorylation is increased in 
hyperplasic adrenal medullas of Pten+/- Trib3-/- animals when compared with the same 
lesion in Pten+/- mice, thus suggesting that loss of Trib3 produces an increase in the 
phosphorylation of AKT that contributes to the malignant progression in this tissue. In 
the same line of reasoning, Trib3-/- mice subjected to the two-step skin carcinogenesis 
protocol generated papillomas of a more aggressive phenotype and with higher levels of 
AKT phosphorylation than papillomas generated in WT littermates. Likewise, tumor 
xenografts generated with RasV12/E1A-transformed Trib3-/- MEFs or with different 
cancer cell lines in which TRIB3 had been knocked-down exhibited an enhanced 
phosphorylation of AKT when compared to their corresponding WT or control siRNA-
transfected counterparts. Taken together, these observations strongly suggest that 
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TRIB3 limits the capacity of AKT to become over-activated in response to oncogenic 
signals. 
Our findings also define the mechanism of the tumor suppressive activity of 
TRIB3 downstream of AKT, which relies on the selective regulation of FOXO3 
activity. Thus, re-expression of a mutant form of FOXO3 in which the residues 
phosphorylated by AKT have been mutated to Ala abolished the enhanced proliferation 
and clonogenicity of TRIB3-deficient cells and re-established the pattern of FOXO-
regulated genes characteristic of WT cells. Furthermore, re-expression of this construct 
decreased proliferation and growth rate of tumors generated withTrib3-deficient cells. 
Although care should be taken in the interpretation of data derived from the 
overexpression of a transcription factor these observations support that FOXO3 
inactivation plays a crucial role in the enhanced tumorigenic features of cells in which 
Trib3 is genetically inactivated. Nevertheless, expression of the FOXO-A3 mutant 
affected the rate of tumor growth but did not modify the time to occurrence of tumors 
derived from Trib3-/- cells, thereby suggesting that - together with the regulation of 
FOXO activity – TRIB3 may use additional mechanisms to control tumorigenesis. 
Further research should therefore clarify the role played by FOXO in the regulation of 
cell survival and proliferation in cells in which TRIB3 has been genetically inhibited 
Likewise, future studies should investigate whether the regulation of additional AKT 
targets (such as BAD) or of other targets of TRIB3 [including for example those 
previously implicated in the control of cell proliferation such as ATF-4, SMAD3 or 
CtIP (3, 31-33)] may also contribute to the tumor-suppressor activity of TRIB3 
TRIB3 has been previously shown to interact with AKT (11, 15), although the 
precise mechanism by which this interaction regulates the activity of the kinase as well 
as the physiological consequences of this inhibition had not been completely clarified 
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yet. Data presented here show that TRIB3 regulates the phosphorylation of AKT by the 
mTORC2 complex. Of potential relevance in this context, Sabatini’s group has shown 
that genetic ablation of the mTORC2 component RICTOR affects the phosphorylation 
of FOXO but not of GSK3 or TSC2 (34), thereby suggesting that phosphorylation of 
AKT in Ser 473 could be sufficient for the kinase to phosphorylate some of its 
substrates. In line with this observation and with the notion that TRIB3 participates in 
the regulation of AKT phosphorylation by mTORC2, we found that genetic inactivation 
of TRIB3 leads to an enhanced phosphorylation of FOXO and BAD, but not of GSK3or 
PRAS 40. Moreover, we recently found that treatment with ǻ9-tetrahydrocannabinol [a 
compound derived from the plant Cannabis sativa that exerts anti-tumor effects in 
mouse models of cancer (14, 15, 35)] triggers AKT inhibition via an enhanced 
interaction of TRIB3 with AKT and a subsequent decrease in the interaction of AKT 
and TRIB3 with the mTORC2 complex (19). Our data also show that Trib3 interacts 
more strongly with WT AKT, or with AKT mutants in which Thr 308 and Ser 473 have 
been mutated to Ala, than with AKT mutants in which these two phosphorylatable 
residues have been mutated to Asp to mimic the negative charge associated with their 
phosphorylation (author’s unpublished observations). Altogether, these observations 
cogently support that the interaction with TRIB3 negatively regulates AKT by 
restricting the access of the kinase to the mTORC2 complex (a schematic of the 
proposed model is shown in Figure 7f). Moreover, our findings also show that TRIB3 
may contribute to the regulation of AKT selectivity for some of its substrates. Of note, 
total Akt levels are increased in Trib3-/- RasV12/E1A-transformed MEFs when 
compared with their corresponding WT counterparts. Although this effect is much less 
pronounced than that of TRIB3 genetic inactivation on Akt phosphorylation and does 
not take place in HepG2 or BT474 cells in which TRIB3 expression was silenced, these 
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observations suggest that TRIB3 may also play a role on the regulation of AKT 
stability.  
Analysis of gene expression profiles of cancer patients from published studies 
reveals that TRIB3 mRNA levels are down-regulated in different tumor types 
(Supplementary Table II and III). Likewise, high TRIB3 protein levels are associated 
with good prognosis in breast cancer patients (36). In addition, TRIB3 is focally deleted 
in tumors of epithelial origin (tumourscape dataset; Supplementary Table I), thus 
supporting that loss or down-regulation of TRIB3 is an event associated with human 
cancer. Nevertheless, other studies have found an up-regulation of TRIB3 mRNA levels 
in human cancers (33, 37). In addition, previous observations by other laboratories 
indicate that TRIB3 can enhance proliferation and invasiveness of cancer cells in vitro 
(31-33), and a recent study has shown that knock-down of TRIB3 produces a moderate 
increase in the growth of orthotopic xenografts generated with MDA-231 breast cancer 
cells (38). A plausible explanation for the apparently contradictory results obtained here 
and in those studies could be the existence of differences in the genetic alterations, the 
degree of differentiation or other relevant phenotypic characteristics in the cell lines 
used in the various studies. In support of this idea, and as shown in the present study, 
silencing of TRIB3 produces heterogeneous effects on the tumorigenic properties of 
different cancer cell lines as it enhances the rate growth of tumors generated with 
U87MG cells (data not shown), accelerates the onset of HepG2 cell-derived tumors, and 
hastens both processes in tumors generated with BT474 cells. Thus, although the 
findings presented here cogently support that genetic inhibition of TRIB3 enhances 
tumorigenesis in several genetic contexts and, specifically, in the presence of activating 
mutations of Ras or the deletion of one of the copies of Pten, further research should 
clarify whether inactivation or enhanced expression of TRIB3 may produce a different 
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outcome in a distinct genetic or cellular context. It is worth noting that it has been 
reported that TRIB3 null animals show up-regulation of TRIB1 and TRIB2 in at least 
some tissues (39). Since TRIB2 is associated with induction of acute myelogenous 
leukemia (AML) (40, 41) and TRIB1 with other malignancies (42, 43), changes in the 
levels of the other Tribbles isoforms may also contribute to the phenotype observed in 
Trib3-/- animals. 
 In summary, results presented here show that genetic inhibition of TRIB3 
increases tumorigenesis in several animal models of cancer and that this effect is due – 
at least primarily – to the enhanced phosphorylation of AKT by the mTORC2 complex 
and the subsequent hyperphosphorylation and inactivation of FOXO3. These results 
may help to set the basis for the development of novel targeted therapies for the 
management of cancer. 
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MATERIALS AND METHODS 
 
A list of the reagents used, primer sequences, antibodies and other materials, together 
with additional details of all techniques used in this study can be found in Supplemental 
Experimental Procedures. 
 
Generation of Trib3
-/-
 mice 
Trib3+/í mice [B6;129S5-Trib3Gt(OST324148)Lex/Ieg obtained from European Mouse 
Mutant Archive, EMMA; ID: EM-02346, LEXKO-1947] were back crossed with 
C57/BL6 for ten generations and were then inter-crossed to generate homozygous 
knockout embryos. This line was developed using the OST324148 OmniBank® ES cell 
line from a sequence tagged gene trap library (44). Briefly, the gene trap vector included 
a two expression cassettes (Suplementary Figure S1a). The first cassette encoded for a 
splice acceptor site (SA), followed by a fusion protein of beta-galactosidase and 
neomycin, thereby disrupting transcription of the targeted mRNA. The second cassette 
encoded for a “diagnostic marker”, followed by a splice donor site and was used to 
determine the site of insertion for the targeting vector by 3’ RACE. Using this gene trap 
vector, the TRIB3 allele was targeted in the first intron. (Supplementary Figure S1b). 
The sequence shown in Supplementary Figure S1C includes 250 nucleotides on either 
side of the insertion site, denoted by an asterisk (data kindly provided by Lexicon 
Pharmaceuticals). Exons 2-4 encode for the TRIB3 Open Reading Frame (highlighted 
in red).Insertion of the gene trap vector prevented the expression of the TRIB3 protein, 
as demonstrated by an anti TRIB3 western blot (Supplementary Figure S1e) and did not 
produce a truncated version of Trib3 as we had previously proposed in a previous work 
(19). 
Generation of Pten
+/-
 Trib3
-/-
 animals 
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Pten
+/- mice (C57/Bl6/J) were kindly provided by Dr Manuel Serrano (Spanish Cancer 
Research Center, Madrid, Spain). Characterization of these animals has been previously 
described (45). Pten+/- mice were crossed with Trib3+/- mice and the progeny 
intercrossed. Animals of the different genotypes were sacrificed at 8 months of age and 
histopathological analyses of different organs were performed.  All procedures 
involving animals were performed with the approval of the Complutense University 
Animal Experimentation Committee in compliance with Spanish and European official 
regulations 
Genotyping 
Tail genomic DNA were isolated using standard procedures. Primers used for PCR 
genotyping were: 5’ CCGCGACGAATGAAAGGTTTA 3’; 5’ 
AGACTCCGAGAGCTGCTCAGTTAGG 3’ for wt (Trib3) allele (483 bp) and 5’ 
CCGCGACGAATGAAAGGTTTA 3’, 5’ 
AAATGGCGTTACTTAAGCTAGCTTGC3’ for KO (Trib3) allele (381 bp). PCR 
conditions were 40 cycles (30 s at 95 °C, 30 s at 65 °C and 30 s at 72 °C; supplementary 
Figure S1). Gentotyping of Pten animals has been previously described (45). 
 
Skin Chemical Carcinogenesis model: animals and treatments 
As pure C57BL6/J mice are refractory to DMBA/ TPA-induced carcinogenesis, Trib3-/- 
animals were bred to the DMBA/TPA-sensitive 129/Ola strain. Heterozygous animals 
from this progeny were inter-crossed to generate the Trib3+/+ and Trib3-/- littermates 
used in this study (129/SvEvBrd_C57BL6/J mixed genetic background). For the two-
stage carcinogenesis experiments, tumors were induced on the shaved dorsal skin of 
WT (n=15) and TRB3 KO (n= 20) mice by topical application of a single dose of 
DMBA (32 mg in 200 ml of acetone), followed by twice-weekly applications of TPA 
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(12.5 mg in 200 ml of acetone) for 20 weeks. The number of tumors (42 mm in 
diameter) was recorded weekly. TPA treatment was ended after 20 weeks, and animals 
were left untreated until week 32 after DMBA initiation to allow the development of 
carcinomas. Tumors were collected at different time points and histologically typed as 
previously described. At the end of the experiments, mice were killed and tumors or 
skin were collected. Samples were divided into portions that were (1) frozen in Tissue-
Tek (Sakura Finetek Europe, Zoeterwoude, The Netherlands) for immunofluorescence 
staining, (2) snap-frozen for protein and RNA extraction or (3) fixed in 10% buffered 
formalin, pH 7.2, for 24-72 hours. All tissues were processed by standard histologic 
techniques for the production of 4 µm thick sections stained with hematoxylin and 
eosin. Skin slides were studied and classified according to the International 
Classification of Rodent Tumours (1993). In four cases of animal death, necropsies 
were performed on all mice within 24 hours of death and samples of cutaneous masses, 
lung, liver, kidney, spleen, stomach, small and large intestine, adrenal and thyroid 
gland, reproductive tract and brain were collected and processed the same way.  
 
Cell culture 
U87MG (human glioma cell line), BT474 (human breast cancer cells) and HEPG2 cells 
(human hepatocellular carcinoma cell line) were obtained from the American Culture 
Collection (Rockville, MD). CarC, CarCR, MSC11B9, MSC11A5, PDV and CarB 
murine skin carcinoma cell lines (see text and Supplementary Experimental procedures 
for further details) were obtained from Miguel Quintanilla. [CarC-R is a less aggressive 
epithelial cell line isolated from the fusocellular carcinoma cell line CarC (21); 
MSC11B9 (B9) and MSC11A5 (A5) cells were derived, respectively, from the 
squamous component and the more undifferentiated region of the same carcinoma (20); 
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PDV cells were derived from a squamous cell carcinoma and CarB cells from a spindle 
cell carcinoma]. 
Trib3
+/+ and Trib3-/- mouse embryonic fibroblasts (MEFs) were extracted as 
previously described (46) and transformed using different retroviral vectors to generate 
RasV12-MEFs, RasV12/E1A-MEFs, SV40 T-large antigen-MEF and 
FOXO3/RasV12/E1A/-MEFs. Transformed/stably transfected MEFs correspond to a 
polyclonal mix of at least 20 different selected clones). Cells were cultured in DMEM 
containing 10% FBS and penicillin/ streptomycin (5µg/ml). When required, cells were 
seeded at a density of 5 000-10 000 cells/cm2 and transferred to medium containing 
0.5% FBS (except RasV12/E1A-transformed MEFs, that were transferred to media 
containing 2% FBS) 18 h before performing the different treatments.  
 
Genetic knock-down by small interfering RNA 
SMARTpool siRNA duplexes (a combination of four siRNAs into a single pool, which 
guarantees an efficiency of silencing of at least 75%; Dharmacon, Lafayette, CO, US) 
were used to transiently silence the expression of the indicated genes. Controls were 
transfected with a non-targeted control siRNA. Transfection efficiency was higher than 
70% as monitored with a control fluorescent (red) siRNA (siGLO RISC-Free siRNA, 
Dharmacon) 
 
Infection with TRB3 shRNA- human lentiviral particles 
A pool of concentrated transduction-ready viral particles containing 3 shRNAs target-
specific (or 3 shRNA non-targeted control) constructs; Santa Cruz Biotechnology; 
Heidelberg, Germany) was used to infect human cancer cell lines. Clones of stably-
silenced (or control shRNA transduced) cells were selected. At least 20 different 
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selected clones were pooled for each of the cell lines generated.  
 
Luciferase assays 
Cells were transfected with a luciferase reporter constructs containing different 
promoters along with a Renilla luciferase expression plasmid (pRL-TK) for 
normalization.  
 
In vivo generation of tumor xenografts 
Tumors were induced by subcutaneous injection in nude mice (Harlan Interfauna 
Iberica, Barcelona, Spain) of 4 x106 cells in PBS supplemented with 0.1% glucose.  
 
Statistics 
Except when otherwise stated, statistical analysis was performed by ANOVA with a 
post-hoc analysis by the Student-Neuman-Keuls test (paired or unpaired). Differences 
were considered significant when the P value was less than 0.05. Wilcoxon signed-rank 
test was used in the analysis of cumulative number of papillomas found in animals 
subjected to the DMBA/TPA treatment. 
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FIGURE LEGENDS 
Figure 1. Genetic inhibition of TRIB3 facilitates oncogene transformation and 
enhances the tumorigenicity of transformed embryonic fibroblasts 
(a) Effect of RasV12 expression on the ability of Trib3+/+ and Trib3-/- mouse embryonic 
fibroblast (MEFs) to form colonies in soft agar (cells were transduced with a retroviral 
vector encoding RasV12)(mean ± SD; n=3; **P < 0.01 from Trib3+/+ MEFs). 
(b) Effect of transduction with a retroviral vector encoding RasV12 or with the empty 
retroviral vector pBABE on Trib3+/+ and Trib3-/- MEFs cell number . Data correspond to 
the number of cells at each time point (as determined by crystal violet staining) relative 
to the number of cells at day 0 for each experimental condition (mean ± SD; n=3; **P < 
0.01 from RasV12-Trib3+/+ MEFs). 
(c) Effect of HA-TRIB3 expression on the percentage of Ki67-positive RasV12/E1A-
transformed Trib3+/+ and Trib3-/- MEFs. Data correspond to the percentage of Ki67-
positive cells relative to the total number of cells in each experimental condition (mean 
± SD; n=4; **P < 0.01 from empty vector-transfected Trib3+/+ cells and ##P < 0.01 
relative to empty vector-transfected Trib3-/- cells). Upper panel: Western blot analysis of 
TRIB3 expression. A representative experiment (n=4) is shown. 
(d)  Effect of HA-TRIB3 expression on the ability RasV12/E1A-transformed Trib3+/+ 
and Trib3-/- MEFs to form colonies in soft agar. (mean ± SD; n=6; **P < 0.01 relative 
to empty vector-transfected Trib3+/+ cells and #P < 0.05 relative to empty vector-
transfected Trib3-/- cells).  
(e) Effect of Trib3 genetic inactivation on the growth of tumor xenografts generated by 
subcutaneous injection of RasV12/E1A-transformed MEFs in nude mice. Data 
correspond to the mean volume change ± SEM at each time point (n=8 for each 
condition; 4 x 106 cells were injected in each experimental condition). Right panel: Data 
correspond to the time elapsed from the injection of the cells until the tumors reach an 
average volume of 250 ± 25 mm3 (mean ± SEM; n=8 for each condition; **P < 0.01 
from tumors generated with Trib3-/- MEFs).  
 
Figure 2. Genetic inhibition of TRIB3 enhances the tumorigenicity of cancer cell 
lines 
(a) Effect of TRIB3 stable knockdown on the ability of BT474 (left panel) and HepG2 
(right panel) cells to form colonies in soft agar. [mean ± SD; n=3; **P < 0.01 relative to 
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BT474 or HepG2 cells stably transduced with a lentiviral vector encoding a control 
(non-targeted) shRNA sequence (shC)].  
(b-c) Effect of TRIB3 stable knockdown on the growth of tumor xenografts generated 
by subcutaneous injection of BT474 (b) and HepG2 (c) cells in nude mice. Data on the 
lower panels correspond to tumor volume [mean ± SEM; n= 6 for each condition; *P < 
0.05 and **P < 0.01 from tumors generated with shC BT474 (b) and shC HEPG2 (c) 
cells]. Upper panels: Data correspond to the time elapsed from the injection of the cells 
until the tumors reach an average volume of 250 ± 25 mm3 (mean ± SEM; n=6 for each 
condition).  
Insets in panels b and c show the expression of human TRIB3 mRNA levels (hTRIB3) 
(as determined by RT-PCR) in tumors generated with shC- and shTRIB3-transduced 
cells.  
 
Figure 3. TRIB3 genetic inactivation accelerates the malignant progression of 
mouse skin papillomas  
(a) TRIB3 mRNA levels as determined by real-time quantitative PCR in different 
mouse skin cancer cell lines. Data are expressed as the mean fold-increase ± SD relative 
to the corresponding less differentiated cell lines (n=3; **P < 0.01 compared to 
undifferentiated cells). 
(b) TRIB3 mRNA levels as determined by real-time quantitative PCR in samples 
derived from normal skin, papillomas, squamous cell carcinomas (SCC) grades I and II 
(SCCI/II) and SCC grades III and IV (SCCIII/IV) obtained from mice subjected to the 
two-stage model of skin carcinogenesis.Data correspond to TRIB3 mRNA levels and 
are expressed as the mean fold change ± SD relative to normal skin (n=8, 8, 6 and 6 for 
normal skin, papillomas, SCCI/II and SCCIII/IV, respectively; ** P < 0.01 from normal 
skin; ##P  < 0.01 from papillomas and ĮĮP < 0.01 from SCC I/II samples).  
 (c) Effect of TRIB3 genetic inactivation on the degree of differentiation and 
aggressiveness of the skin lesions appeared in Trib3-/- and Trib3+/+ mice subjected to the 
two-stage skin carcinogenesis protocol. (Animals were sacrificed 20 or 32 weeks after 
the administration of the DMBA treatment and subsequently subjected to 
hystopathological analyses). Data are expressed as the mean number of squamous 
papillomas or squamous papillomas with dysplasia per animal ± SEM. [week 20: 6 
Trib3
+/+ and 5 Trib3-/-mice; week 32:  7 Trib3+/+ and 9 Trib3-/- mice; **P < 0.01 or *P < 
0.05 fromTrib3+/+ animals].  
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(d) Representative images of hematoxilin/eosin (upper panel, 2x) and PCNA staining 
(lower panel, 10x) of squamous papillomas and squamous papillomas with severe 
dysplasia observed in Trib3+/+ and Trib3-/- mice. See also Supplementary Fig S3. 
 
 
Figure 4. Loss of TRIB3 enhances the phosphorylation of AKT in cancer cells via 
mTORC2 
(a) Effect of TRIB3 genetic inactivation on AKT phosphorylation of RasV12/E1A-
transformed MEFs. Values below each of the Western blots correspond to the 
densitometric analysis of the ratio Phospho-Akt (P-Akt)/tubulin and total Akt (t-
Akt)/tubulin respectively and are expressed as the mean fold change ± s.d. relative to 
Trib3
+/+ cells. Data on the right panel correspond to the P-Akt/t-Akt ratio and are 
expressed as the mean fold change ± s.d. relative to Trib3+/+ cells. (n=4; ** P < 0.01 
from Trib3+/+ cells) 
(b) Effect of TRIB3 genetic inactivation (left panel) or stable knockdown (middle and 
right panel) on AKT phosphorylation as determined by Western blot analysis of tumor 
xenografts generated by subcutaneous injection of RasV12/E1A-transformed MEFs (left 
panel), HepG2 (middle  panel) and BT474 (right panel) cells in nude mice. Data 
correspond to the densitometric analysis of AKT phosphorylation expressed as the P-
Akt/t-Akt ratio  relative to Trib3+/+-MEFs (left panel), shC BT474 (middle panel) or 
shC BT474 (right panel) tumors (n=3; mean ± SD) [**P < 0.01 from tumors generated 
with Trib3+/+ MEFs, shC HEPG2 or shC BT474 cells]. 
(c) Effect of TRIB3 genetic inactivation on AKT phosphorylation of cutaneous 
squamous papillomas. Representative images (40x) of P-AKT and t-AKT 
immunohystochemistry staining from 3 cutaneous squamous papillomas per 
experimental condition are shown.  
(d) Effect of HA-TRIB3 expression on the phosphorylation of Akt on Thr 308 and Ser 
473 of RasV12/E1A-transformed Trib3-/- MEFs (n=3, a representative experiment is 
shown). Upper panel: AKT was immunoprecipitated from cell extracts obtained from 
RasV12/E1A-transformed Trib3+/+ or Trib3-/- MEFs transfected with an empty vector 
(pCDNA) or a plasmid encoding HA-TRIB3. Lower panel: Analysis of total AKT and 
HA-TRIB3 levels in the corresponding whole cell extracts (samples were loaded by 
duplicate).  
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(e) Effect of RICTOR knock-down (left panel) or incubation in the presence of torin1 
(250 nM, 18 h; right panel) on the phosphorylation of AKT on Ser 473 of RasV12/E1A-
transformed Trib3+/+ or Trib3-/- MEFs (n=3; a representative Western blot analysis is 
shown). Values below each of the Western blots correspond to the P-Akt/t-Akt ratio and 
are expressed as the mean fold change ± s.d. relative to shC, Trib3+/+ (left panel) or veh-
treated Trib3+/+ (right panel) cells. [n=3; ** P < 0.01 from shC Trib3+/+ (left panel) or 
veh-treated shC Trib3+/+ (right panel) cells and ## P < 0.01 from shC Trib3-/- cells (left 
panel) or from veh-treated Trib3-/- (right panel) cells] 
(f) Effect of RICTOR knock-down on the number (as estimated by the MTT test) of 
RasV12/E1A-transformed Trib3+/+ and Trib3-/- MEFs. Data are expressed as themean 
fold increase ± SD relative to siC Trib3+/+ MEFs at 24 h; (n=4; **P < 0.01 from siC-
transfected Trib3+/+ MEFs; ##P < 0.01 from siC-transfected Trib3-/- MEFs).  
(g) Effect of RICTOR knock-down on the ability of RasV12/E1A-transformed Trib3+/+ 
and Trib3-/- MEFs to form colonies in soft agar (n=3. Images of one representative 
experiment are shown).  
(e-g) Transfection with RICTOR siRNA reduced RICTOR mRNA levels (as 
determined by quantitative real-time PCR) of Trib3+/+ and Trib3-/- cells by 83±1 % and 
91±2 % respectively (p < 0.01 from the corresponding siC-transfected RasV12/E1A-
MEFs; n=4).  
 
Figure 5. Loss of TRIB3 enhances the incidence of premalignant and malignant 
lesions in Pten
+/- 
mice. 
(a) Effect of the genetic inactivation of TRIB3 on the incidence of premalignant and 
malignant lesions in the adrenal glands of Pten+/- mice. Data are expressed as the 
percentage of animals of each genotype that exhibit hyperplasia of the adrenal glands 
(upper panel) or pheocromocytomas (middle panels). Bottom panel: Representative 
microphotographs (10x) of the different lesions observed in the adrenal glands of Pten+/- 
Trib3
+/- and Pten+/- Trib3-/- animals stained with hematoxilin/eosin.  
(b) Representative microphotographs of anti-phospho AKT and total Akt 
immunostaining of the adrenal glands of wild type, Pten+/- and Pten+/- Trib3-/- animals. 
Note that the hyperplasic region located in the medulla of the adrenal gland exhibits 
strong phospho-AKT immuno-staining in Pten+/- Trib3-/- mice but not in Pten+/- mice 
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(n=3; 40x). Insets show details of the different panels at higher magnification. See also 
Supplementary Figure S5. 
 
Figure 6.  Loss of TRIB3 promotes FOXO inactivation 
(a) Effect of TRIB3 genetic inactivation on the phosphorylation of FOXO, of 
RasV12/E1A-transformed MEFs Values below the Western blots correspond to the 
densitometric analysis of the ratio Phospho-FOXO (P-FOXO)/tubulin and total FOXO 
(t-FOXO)/tubulin respectively and are expressed as the mean fold change ± s.d. relative 
to Trib3+/+ cells. Data on the right panel correspond to the P-FOXO/t-FOXO ratio and 
are expressed as the mean fold change ± s.d. relative to Trib3+/+ cells. (n=4; ** P < 0.01 
from Trib3+/+ cells) 
(b) Effect of TRIB3 re-expression (upper panel), and RICTOR knock-down (lower 
panel) on the phosphorylation of FOXO, of RasV12/E1A-transformed Trib3+/+ and 
Trib3-/- MEFs. Values in the bottom of the panels correspond to the P-FOXO/t-FOXO 
ratio and are expressed as the mean fold change ± s.d. relative to pCDNA Trib3+/+ 
(upper panel) or siC-transfected Trib3+/+ (lower panel) MEFs. [n=3;** P < 0.01 and * P 
< 0.05 from pCDNA Trib3+/+ (upper panel) or siC-transfected Trib3+/+ (lower panel) 
cells. Transfection with RICTOR siRNA reduced RICTOR mRNA levels (as 
determined by quantitative real-time PCR) of Trib3+/+ and Trib3-/- cells by 83±1 % and 
91±2 % respectively (n=4; P < 0.01 from the corresponding siC-transfected 
RasV12/E1A-MEFs). 
(c) Effect of serum withdrawal on the sub-cellular distribution (as determined by 
cellular fractionation and subsequent Western blot analysis of cytosolic and nuclear 
fractions) of endogenous FOXO in RasV12/E1A-transformed Trib3+/+ and Trib3-/- 
MEFs. ȕ-actin was used as loading control. Ițȕ-α and Lamin A/B were used as markers 
of the cytosolic and the nuclear fractions, respectively (n=3; a representative experiment 
is shown).  
(d) Effect of serum withdrawal on the activity of the Bim promoter of RasV12/E1A-
transformed Trib3-/- MEFs transfected with a vector encoding HA-TRIB3 or a control 
plasmid and co-transfected with a luciferase reporter vector containing the sequence of 
the Bim promoter (WT or mutated on the FOXO binding sites). Data correspond to the 
luciferase activity and are expressed as the mean fold increase ± SD relative to HA-
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TRIB3-transfected Trib3-/- cells incubated in the presence of serum (n=3; *P < 0.05 
from serum-treated HA-TRIB3-transfected Trib3-/- cells).  
(e) Effect of TRIB3 genetic inactivation (e, left panel) or stable knockdown (e, middle 
and right panels ) on FOXO phosphorylation as determined by Western blot analysis of 
tumor xenografts generated by subcutaneous injection of RasV12/E1A-transformed 
MEFs (left panel), HepG2 (middle panel) and BT474 cells (right panel) in nude mice.  
  Values in the bottom of the panels correspond to the P-FOXO/t-FOXO ratio and are 
expressed as the mean fold change ± s.d. relative to Trib3+/+ tumors (left panel) or shC 
HepG2 tumors (middle panel) or shC BT474 tumors (right panel) [n=3; ** P < 0.01 or * 
P < 0.05 fromtumors generated with Trib3+/+ MEFs, shC HEPG2 or shC BT474 cells].  
(f) Effect of TRIB3 genetic inactivation on FOXO3 phosphorylation of cutaneous 
squamous papillomas. Representative images (40x) of phospho-FOXO1/3 or total 
FOXO3 immunohistochemistry staining from 3 cutaneous squamous papillomas per 
experimental condition are shown. See also Supplementary Figure S6. 
 
Figure 7. Loss of TRIB3 enhances tumor growth via FOXO inactivation  
(a) Upper panel: Analysis of FOXO protein levels in RasV12/E1A-transformed Trib3+/+ 
and Trib3-/- MEFs stably transfected with a constitutively active version of FOXO 
(FOXOA3) or the corresponding empty vector (pBABE). Lower panel: Sub-cellular 
distribution (as determined by cellular fractionation and subsequent Western blot 
analysis of cytosolic and nuclear fractions) of FOXO protein in RasV12/E1A-
transformed Trib3-/- MEFs stably transfected with FOXOA3. ȕ-actin was used as 
loading control. Ițȕ-α and Lamin A/B were used as markers of the cytosolic and the 
nuclear fractions, respectively (n=3; a representative experiment is shown).  
(b) Effect of TRIB3 genetic inactivation and stable expression of FOXOA3 on the 
number of   RasV12/E1A-transformed MEFs (as estimated by the MTT test) at the 
indicated time points. Data are expressed as the mean fold change ± SD  relative to 
pBABE-Trib3+/+ cells at 24 h (mean ± SD; n=3; **P < 0.01 from pBABE-Trib3+/+ cells; 
##
P < 0.01 from pBABE-Trib3-/- cells).  
(c) Effect of TRIB3 genetic inactivation and stable expression of FOXOA3 on the 
ability of RasV12/E1A-transformed MEFs to form colonies in soft agar (n=3. A 
representative experiment is shown).  
(d) Effect of FOXOA3 stable expression and TRIB3 genetic inactivation on the growth 
of tumor xenografts generated by subcutaneous injection of RasV12/E1A-transformed 
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MEFs in nude mice data are expressed as the mean tumour volume ± SEM for each 
experimental condition (n=8 for each condition; volume of Trib3-/- FOXOA3 cell-
derived tumor is compared with that of tumors derived from Trib3-/- pBabe cells; **P < 
0.01 from pBABE-Trib3-/- cell-derived tumors). Lower panel: analysis of FOXO protein 
levels in tumors derived from FOXOA3-Trib3-/- and pBABE-Trib3-/- cells.  
(e) Analysis of Ki67 immunostaining in samples from tumors derived from pBABE-
Trib3
+/+, pBABE-Trib3-/- and FOXOA3-Trib3-/- cells. Values in the lower right corner of 
microphotographs  correspond to the Ki67–stained area relative to the total number of 
nuclei in each section and are expressed as the mean fold change relative to pBABE-
Trib3
+/+ tumors ± SD. (**P < 0.01 from pBABE-Trib3+/+ tumors; ##P < 0.01 from 
pBABE-Trib3-/- tumors; 18 sections for each of 3 dissected tumors for each condition 
were counted). Representative microphotographs are shown.  
(f) Proposed model of the mechanism by which TRIB3 controls tumorigenesis. TRIB3 
interacts with AKT, which regulates the phosphorylation of the kinase by the mTORC2 
complex (left panel). Genetic inhibition of TRIB3 in combination with different 
oncogenic signals facilitates the hyper- phosphorylation of AKT on Ser 473 by the 
mTORC2 complex and the subsequent hyper-phosphorylation and inactivation of the 
transcription factor FOXO3 (as well as of the BH3-only protein BAD) but not of other 
AKT downstream targets. The hyper-phosphorylation and inactivation of FOXO is 
responsible - at least in part - for the enhanced tumorigenic features of TRIB3-deficient 
cells. See also Supplementary Figure S7 and Supplementary Table II. 
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Wild Type
n=14 
Trib3 +/-
n=9 
Trib3 -/- 
n=12 
Pten +/- 
n=8 
Pten +/- 
Trib3 +/- 
n=14 
Pten +/- 
Trib3 -/- 
n=9 
Lymph node       
Lymphoid hyperplasia 
submandibular 
 
0 %
 
0 %
 
0 %
 
62 %
 
57 % 
 
67 %
Lymphoid hyperplasia 
abdominal ganglea 
 
0 % 
 
0 % 
 
0 % 
 
0 % 
 
0 % 
 
22 % 
Thyroid       
Hyperthyroidism 0 % 11 % 0 % 12 % 64 % 55 % 
Thyroid adenoma 0 % 0 % 0 % 0 % 14 % 11 % 
Liver       
Lymphoid infiltrates 0 % 0 % 8 % 12 % 0 % 0 %
Steatohepatitis 0 % 0 % 0 % 0 % 7 % 11 % 
Intestine       
Adenoma 0 % 0 % 0 % 12 % 7 % 11 % 
Spleen       
Lymphoid hyperplasia 0 % 0 % 0 % 0 % 0 % 11 % 
       
 Wild Type
n=9 
Trib3 +/-
n=5 
Trib3 -/- 
n=4 
Pten +/- 
n=4 
Pten +/- 
Trib3 +/- 
n=12 
Pten +/- 
Trib3 -/- 
n=3 
Anterior Prostate       
Hyperplasia 11 % 0 % 0 % 75 % 100 % 100 % 
Adenoma 0 % 0 % 0 % 25 % 36 % 67 % 
PIN 0 % 0 % 0 % 50 % 63 % 33 %
Dorsal Prostate       
Hyperplasia 11 % 0 % 0 % 50 % 83 % 100 % 
Adenoma 0 % 0 % 0 % 0 % 25 % 0 % 
PIN 0 % 0 % 0 % 50 % 75 % 100 % 
 
 
Table I. Loss of TRIB3 accelerates the formation of premalignant and malignant 
lesions in Pten
+/-
 mice 
Incidence of pre-malignant and malignant lesions (as determined by hystophatological 
analysis) in different tissues and organs of 8 month-old wild type, Trib3+/-, Trib3-/-, 
Pten
+/-, Pten+/- Trib3+/- and Pten+/- Trib3-/- mice. 
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Salazar et al. Supplementary Figure S1 (cont) 
Supplementary Figure S1. Genetic inhibition of TRIB3 facilitates oncogene transformation and 
enhances the tumorigenicity of transformed embryonic fibroblasts.  
(a-e) Generation of Trib3-/- mice using the gene-trap system. (a) The gene trap vector used to inactivate 
the Trib3 allele included two expression cassettes. The first cassette encoded for a splice acceptor site 
(SA), followed by a fusion protein of beta-galactosidase and neomycin, thereby disrupting transcription 
of the targeted mRNA. The second cassette encoded for a “diagnostic marker”, followed by a splice 
donor site and was used to determine the site of insertion for the targeting vector by 3’ RACE. (b) 
Schematic showing the Trib3 allele, which was targeted in the first intron using the gene-trap vector. (c) 
The sequence includes 250 nucleotides on either side of the insertion site, denoted by an asterisk 
(data kindly provided by Lexicon Pharmaceuticals). (d) PCR amplification (performed on genomic DNA 
obtained from Trib3+/+, Trib3+/- and Trib3-/- mice) of the region where the gene trap vector is inserted 
(Forward primer hybridizes on Trib3 exon-1 and reverse primers hybridize on intron 1-2 of the wild type 
allele and on the 5’ region of the gene-trap vector, respectively). (e) Insertion of the gene trap vector 
prevents the expression of the TRIB3 protein. The panel shows TRIB3 protein levels as determined by 
immunoprecipitation and subsequent Western blot analysis in lysates obtained from cells derived from 
Trib3+/+ and Trib3-/- animals. (f) Effect of the expression of SV-40 T-large antigen on the ability of Trib3+/
+ and Trib3-/- MEFs to form colonies in soft agar (cells were transduced with a retroviral vector encoding 
SV-40 T-large antigen). Data correspond to the number of colonies formed per dish in each 
experimental condition (mean ± SD; n = 3; **P < 0.01 relative to Trib3+/+ MEFs). (g) Effect of the 
expression of SV-40 T-large antigen on the number of Trib3+/+ and Trib3-/- MEFs after several days in 
culture. Data correspond to the number of crystal-violet positive cells at each time point relative to the 
number of cells at day 0 for each experimental condition (mean ± SD; n = 3; **P < 0.01 relative to 
SV40-T large antigen-Trib3+/+ MEFs).  
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Salazar et al. Supplementary Figure S2 
Supplementary Figure S2. Genetic inhibition of TRIB3 enhances the viability of 
cancer cell lines 
Effect of TRIB3 stable knock-down on the number of shC and shTRIB3 BT474 (a) and 
HEPG2 (b) cells (as estimated by the MTT test) (mean ± SD; n = 5; **P < 0.01 from shC 
cells at each time point).  
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Supplementary Figure S3. Analysis of the effect of TRIB3 genetic deletion on the incidence 
of mouse skin carcinomas  
(a) Effect of TRIB3 genetic inactivation on the incidence of skin carcinomas in Trib3-/- and Trib3+/+ 
mice subjected to the two-stage skin carcinogenesis protocol (animals were sacrificed 20 or 32 
weeks after the administration of the DMBA treatment and subsequently subjected to 
hystopathological analyses). Data are expressed as the mean number of squamous cell 
carcinomas per animal ± SEM) [7 Trib3+/+ and 9 Trib3-/- mice sacrificed on week 32 were analyzed]. 
(b,c) Representative images of hematoxilin/eosin (b, left panels: 2x, right upper panel: 20x and 
right lower panel: 40x) and PCNA staining (c; left panels: 2x; right panels: 10x) of squamous 
carcinomas or in situ carcinomas observed in Trib3-/- mice.  
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Supplementary Figure S4. Genetic inhibition of TRIB3 enhances the viability of cancer cell 
lines via AKT 
(a) Effect of TRIB3 stable knockdown on AKT phosphorylation of BT474 and HepG2 cells (n = 3; a 
representative Western blot for each cell line is shown). Values in the bottom of each Western blot 
correspond to the P-AKT/t-AKT ratio and are expressed as the mean fold change ± SD relative to the 
corresponding shC cells; *P < 0.05 from shC cells). (b,c) Effect of TRIB3 stable knock-down and the 
AKT inhibitor X (1 µM; 24 h) on the number of BT474 (b) and HEPG2 (c) cells (as estimated by the 
MTT test) at the indicated time points (mean ± SD; n = 5; **P < 0.01 from shC vehicle-treated cells 
and ##P < 0.01 from shTRIB3 vehicle-treated cells). (d) Effect of TRIB3 re-expression on the 
phosphorylation of AKT on Ser 473 of RasV12/E1A-transformed Trib3+/+ or Trib3-/- MEFs (a 
representative Western blot analysis is shown). Values in the bottom of the panels correspond to the 
P-AKT/t-KT ratio and are expressed as the mean fold change ± s.d. relative to pCDNA-transfected, 
Trib3+/+ cells [n=3; ** P < 0.01 from pCDNA-transfected Trib3+/+ cells]. 
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Supplementary Figure S5. Characterization of premalignant and malignant lesions in 
thyroid and prostate of Pten+/-   Trib3-/- mice 
(a,b) Representative microphotographs of the different lesions observed in the thyroid (a: 10x) 
and the prostate (b; upper panels: 10x, middle-lower left panels: 10x and middle-lower right 
panels: 40x) of Pten+/+ Trib3+/+ (WT) and Pten+/- Trib3-/- animals stained with hematoxilin/eosin.  
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Supplementary Figure S6. Genetic inhibition of TRIB3 enhances the proliferation of cancer cell 
lines via AKT-dependent FOXO activation. 
(a) Effect of TRIB3 genetic inactivation on the phosphorylation of BAD, PRAS40, GSK3 and S6 of RasV12/
E1A-transformed MEFs (n=8; a representative experiment is shown). (b) Effect of TRIB3 stable 
knockdown on FOXO (upper panel) and S6 (lower panel) phosphorylation of BT474 and HepG2 cells (n=3; 
a representative Western blot for each cell line is shown). Values below the Western blots correspond to 
the densitometric analysis of the P-FOXO/t-FOXO levels (upper panel) or of the P-S6 levels with respect 
the loading control and are expressed as the mean fold change ± SD relative to the corresponding shC 
cells; **P < 0.01 from shC cells). (c) Effect of TRIB3 re-expression (upper panel), and RICTOR knock-
down (lower panel) on the phosphorylation of BAD and PRAS40 of RasV12/E1A-transformed Trib3+/+ and 
Trib3-/- MEFs (n=3; representative experiments are shown). RICTOR mRNA levels (as determined by real-
time quantitative PCR) were reduced by 87±4 % in siRICTOR-transfected cells with respect to the levels of 
this mRNA in siC-transfected cells). (d) Effect of torin1 treatment (250nM, 18h) on the phosphorylation of 
FOXO (upper panel), BAD and PRAS 40 (lower panel) of RasV12/E1A-transformed Trib3+/+ and Trib3-/- 
MEFs. Upper panel: values below the Western blot correspond to the densitometric analysis of the ratio P-
FOXO/t-FOXO and are expressed as the mean fold change ± s.d. relative to vehicle-treated (veh) Trib3+/+ 
cells. (n=3; ** P < 0.01 from Trib3+/+ cells) Lower panel: n=3; a representative experiment is shown. (e) 
Effect of serum withdrawal on the activity of the Bim promoter of RasV12/E1A-transformed Trib3+/+ and 
Trib3-/- MEFs transfected with a vector encoding FOXO wild type and co-transfected with a luciferase 
reporter vector containing the sequence of the Bim promoter [wild type (wt) or mutated on the FOXO 
binding sites]. Data correspond to luciferase activity and are expressed as the mean fold change ± SD 
relative to the corresponding Bim promoter (wt)-transfected cells incubated in the presence of serum (n = 
4; *P < 0.05 from serum-starved, Bim promoter (wt)- and FOXO3 (wt)-transfected cells). (f-h) Effect of 
TRIB3 stable knockdown or TRIB3 genetic inhibition  on proliferation (as determined by Ki67 
immunostaining) of tumor xenografts generated by subcutaneous injection of HepG2 cells (f) BT474 cells 
(g) and RasV12/E1A-transformed MEFs (h) in nude mice. For the immunostaining, values in the lower right 
corner of each panel correspond to the Ki67-positive cells normalized to the total number of nuclei in each 
section and are expressed as the mean fold change ± SD relative to control tumors (18 sections for each 
of 3 dissected tumors for each condition were analyzed; **P < 0.01 from tumors generated with control 
cells).  
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Supplementary Figure S7. Loss of TRIB3 abrogates the FOXO-dependent activation of the Bim 
promoter in response to serum withdrawal   
(a) Effect of TRIB3 genetic inactivation and stable expression of FOXOA3 on mRNA levels of different 
genes (as determined by real-time quantitative PCR) of RasV12/E1A-transformed Trib3-/- MEFs (mean fold 
change relative to pBABE-Trib3+/+ cells ± SD; n=3; **P < 0.01 from pBABE Trib3+/+ cells ; ##P < 0.01 from 
pBABE-Trib3-/- cells). (b,c) Effect of serum withdrawal on the activity of the Bim promoter of RasV12/E1A-
transformed Trib3+/+ (b) and Trib3-/- (c) MEFs transfected with a vector encoding FOXO wild type or 
FOXOA3 and co-transfected with a luciferase reporter vector containing the sequence of the Bim promoter 
[wild type (wt) or mutated on the FOXO binding sites]. Data correspond to luciferase activity and are 
expressed as the mean fold change ± SD relative to the corresponding Bim promoter (wt)-transfected cells 
incubated in the presence of serum (n = 4; *P < 0.05 from serum-starved, Bim promoter (wt)- and FOXO3 
(wt)-transfected cells and #P < 0.05 from serum-starved, Bim promoter (wt)- and FOXOA3-transfected 
cells). 
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Supplementary Table I. Cancer subtypes in which the chromosomal region 
where Trib3 gene is located has been found to be deleted 
Data shown in the table were obtained from tumor scape data base and show that a 
portion of chromosome 20 containing the indicated number of genes, including Trib3, 
has been found to be deleted in tumors from the indicated origins (data were obtained 
from : 
http://www.broadinstitute.org/tumorscape/pages/portalHome.jsf?mode=publicHome) 
 
Cancer Subset In Peak? Nearest Peak 
#Genes in 
Peak 
Q-value
Frequency of Deletion 
Overall Focal High-level
all_cancers No chr20:95685-297306 10 0,00217 0,1364 0,0364 0,0019 
all_epithelial Yes chr20:95685-667854 17 0,165 0,163 0,0362 0,0026 
Lung NSC Yes 
chr20:95685-
2458642 
37 0,191 0,2319 0,045 0,0027 
Breast Yes chr20:95685-667854 17 0,231 0,1564 0,0453 0,0082 
all_lung Yes 
chr20:95685-
1818755 
30 0,28 0,2287 0,0439 0,0026 
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Supplementary Table II. Decreased TRIB3 expression in human cancer samples 
Cancer samples coming from 206 public experiments were investigated by the authors 
(Gene Expression Atlas - E-MTAB-62). The study compares the different cancer types 
to each other. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tumor type 
database 
entry 
UP/ 
DOWN  
T-Statistic  P-Value publication 
brain tumor 
Gene 
Expression 
Atlas - E-
MTAB-62 
DOWN  -9.9 < 1 × 10-10 (2) 
ovarian 
tumor 
Gene 
Expression 
Atlas - E-
MTAB-62 
DOWN -10 < 1 × 10-10 (2) 
germ cell 
tumor 
Gene 
Expression 
Atlas - E-
MTAB-62 
DOWN  -5.8 2.61 × 10-8 (2) 
uterine 
tumor 
Gene 
Expression 
Atlas - E-
MTAB-62 
DOWN  -9.6 < 1 × 10-10 (2) 
bladder 
cancer 
Gene 
Expression 
Atlas - E-
MTAB-62 
DOWN  -3.3 2 × 10-3 (2) 
oral 
squamous 
cell 
carcinoma 
Gene 
Expression 
Atlas - E-
MTAB-62 
DOWN  -3.5 1 × 10-3 (2) 
acute 
myeloid 
leukemia 
Gene 
Expression 
Atlas - E-
MTAB-62 
DOWN -12 < 1 × 10-10 (2) 
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Supplementary Table III. Selection of individual studies where decreased TRIB3 
expression was detected 
In these studies tumor samples were directly compared to normal tissue 
 
Tumor type 
database 
entry 
UP/ 
DOWN  
T-Statistic P-Value publication 
breast 
tumor cells 
GEO - 
GSE7515 
DOWN  -4.9 1 × 10-3 (3) 
astrocytic 
tumor 
Gene 
Expression 
Atlas - E-
MEXP-567  
DOWN   -3.4 4.7 × 10-2 (4) 
pituary 
cancer 
GEO - 
GSE26966 
DOWN  -3.4 2.21 × 10-5 (5) 
ovarian 
serous 
carcinoma 
GEO - 
GSE14001 
DOWN  -4.4 1 × 10-3 (6) 
peripheral 
T-cell 
lymphoma 
GEO-
GSE19069 
DOWN -11 < 1 × 10-10 (7) 
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SUPPLEMENTARY METHODS 
 
MEFs isolation 
 
Mice (heterozygous for the gene of interest) were crossed and pregnant females were 
sacrificed on gestational day 13.5 to 14.5. Uterus (containing the embryos) was 
extracted and placed in a sterile 10 cm diameter dish; the amniotic sac was removed, 
and the embryos were dissected discarding the limbs, gut, liver and head (genomic 
DNA obtained from head were used for genotyping TRIB3). The remaining tissue was 
minced, incubated with trypsin at 37°C for 5 min, pipetted up and down to eliminate all 
clumps and incubated for 5 additional min at 37°C. Cell suspensions were transferred to 
15 cm diameter plates with 25 ml of DMEM supplemented with 10% FBS and 
antibiotics. Medium was replaced 8-16 h after plating. 
 
MEFs transformation using retroviral vectors 
MEFs were transduced with supernatants enriched in retroviral particles, obtained from 
Phoenix Ecotropic cells. These cells (packaging cells) were plated in 10 cm diameter 
dishes with fresh medium (DMEM with 10% FBS). Cells reached 90% confluence on 
day of transfection. The day after, the Phoenix Ecotropic cells were transfected with a 
plasmid encoding a retroviral vector that includes the gene of interest using 
Lipofectamine 2000 (according to manufacturer´s instructions; Invitrogen). After 
transfection, cells were incubated at 37°C / 5% CO2 for 4-6 h and the medium was 
removed and replaced by fresh complete medium. In parallel, the day after transfection, 
MEFs (from wild-type and KO MEFs littermates) were plated in 10 cm diameter dishes 
with fresh complete medium (DMEM with 10% FBS), reaching 80 to 85% confluence 
on the day of infection. Forty-eight hours after transfection, the medium from Phoenix 
Ecotropic cells was collected, centrifuged to eliminate cell debris and filtered (0.45 µm). 
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Polybrene was added (5 µg/ml) to enhance the efficacy of retroviral transduction. 
Finally, the medium was removed from MEFs, the retroviral-enriched supernatant 
added and cells incubated at 37°C / 5% CO2. The selection of transformed cells was 
performed with puromycin 3 or 4 days after transducing the cells with the retroviral 
particles. The concentration of antibiotics was increased gradually. Individual clones of 
puromycin-resistant cells were evident after several weeks of incubation in the selection 
medium. Individual clones were collected and amplified and the expected genotype was 
verified. 
pBABE retroviral vectors were used to generate Trib3+/+ and Trib3-/- MEFs 
stably expressing the following product genes: RasV12 /E1A (pBABE-RasV12 /E1A),  
RasV12 (pBABE-RasV12), SV40 – T large antigen (pBABE-SV40) or FOXO3aA3 
(pBABE-FOXOA3). The vectors were kindly donated by Dr. Pier Paolo Pandolfi 
(Harvard Medical School, Boston, Massachusetts, US; pBABE-RasV12 /E1A, pBABE-
RasV12 and pBABE-SV40) and by Dr. Clemens A. Schmitt (Max Delbrück Center, 
Berlin, Germany; pBABE-FOXO and pBABE FOXOA3). 
 
Whole Genome Array process and data analyses 
Whole genome expression characterization was conducted using MouseWG-6 v2.0 
Expression BeadChips (Illumina Inc.). cRNA synthesis was obtained with  
TargetAmp™ Nano-g™ Biotin-aRNA Labeling Kit for the Illumina® System, 
Epicentre (Cat.Num. TAN07924) and subsequent amplification, labeling and 
hybridization were performed according to Whole-Genome Gene Expression Direct 
Hybridization Illumina Inc.'s protocol. Raw data were extracted with GenomeStudio 
analysis software (Illumina Inc.), in the form of GenomeStudio’s Final Report (sample 
probe profile).  
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Sample intensity profiles showed no problems on stardard quality controls (e.g. 
intensity distributions and sample correlation). Raw expression data were background-
corrected, log2-transformed and quantile-normalized using the lumi R package (8), 
available through the Bioconductor repository. Probes with a detection p-value lower 
than 0.01 in at least one sample were regarded as detected. For the detection of 
differentially expressed genes, a linear model was fitted to the probe data and empirical 
Bayes moderated t-statistics were calculated using the limma package (9) from 
Bioconductor. 
 
Genetic knock-down by small interfering RNA 
Mouse embryonic fibroblasts (MEFs) were transfected with siRNA duplexes using 
Dharma-FECT 1 Transfection reagent (Dharmacon, Lafayette, CO, US). Twenty-four 
hours after transfection, cells were trypsinized and seeded at a density of 5 000 
cells/cm2. Transfection efficiency was higher than 70% as monitored with a control 
fluorescent (red) siRNA (siGLO RISC-Free siRNA, Dharmacon). Human siRNAs to 
knock down RICTOR were purchased from Dharmacon as a SMARTpool. These 
reagents combine four SMARTselection designed siRNAs into a single pool, which 
guarantees an efficiency of silencing of at least 75%. The double stranded siRNA in all 
cases were designed and synthesized by Dharmacon. The non-targeted control (5’-
UUCUCCGAACGUGUCACGU- 3’), was synthesized by Eurogentec (Liege, 
Belgium). 
 
Infection with TRIB3 shRNA- human lentiviral particles 
A pool of concentrated transduction-ready viral particles containing 3 shRNAs target-
specific (or 3 shRNA non-targeted control) constructs (19-25 nt plus hairpin) (Santa 
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Cruz Biotechnology; Heidelberg, Germany) was used to stably knock-down the 
expression of TRIB3 in several tumor cell lines.  
Briefly, cells were plated in 12-well dishes 24 h prior to viral infection. The day after, 
when the cells reached 50% confluence, medium was removed and replaced by 
complete medium with polybrene at a final concentration of 5µg/ml. Cells were 
subsequently infected with control- or TRB3-selective shRNA lentiviral particles. The 
day after, the medium was removed and replaced by complete medium without 
polybrene. Finally, to select the clones stably expressing the shRNAs, the cells were 
incubated with puromycin 2 to 10 µg/ml. Finally clones were selected and stable 
silencing confirmed by different approaches. At least 20 different selected clones were 
pooled for each of the cell lines generated. Following this procedure, we generated and 
tested the following cell lines: U87MG, HEPG2 or BT474 shC and shTRB3 cells. 
Transformed/stably transfected MEFs correspond to a polyclonal mix of at least 20 
different selected clones 
 
Transfections of expression vectors 
Transfections of expression vectors were performed with Lipofectamine 2000 according 
to the manufacturer´s instructions (Invitrogen). See Supplemntal Experimental 
procedures for a list of the plasmids used in this study.  The plasmids pCDNA, pCDNA-
HA-TRIB3 (kindly provided by Dr. Dario Alessi and Dr. Maria Deak; University of 
Dundee, Dundee, UK), pEBG-GFP, pEBG-PKBĮ, pEBG-pKB ǻPH, pEBG-PKB 
T308A, pEBG-PKB S473A, pEBG-PKB T308A/S473A, pEBG-PKB T308D, pEBG-
PKB S473D, pEBG-PKB T308D/S473D (kindly provided by Dr. Jose Lizcano; 
Department of Biochemistry, Autonoma University, Barcelona, Spain), pCDNA-
FOXO3a WT, pCDNA-FOXO3a (A3) (kindly provided by Dr. Pier Paolo Pandolfi) 
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were used throughout this work. For luciferase assays, the Firefly luciferase reporter 
plasmid containing 0.8 Kb of the bim promoter sequence along with a similar construct 
with mutated FOXO3 binding sites was kindly provided by Eric Lam (Imperial College 
London, London, UK). The pRL-TK (TK-Renilla luciferase) was a kind gift from B.M. 
Burgering (University Medical Center, Utrecht, The Netherlands). 
 
Cell viability assays 
Cell viability was determined by the MTT [(3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, a yellow tetrazole] test (Sigma Aldrich) following the 
manufacturer´s instructions. Its absorbance at 570 nm, which is proportional to the 
amount of viable cells in the culture, was quantified by a spectrophotometer. 
 
Luciferase assays 
Cells were transfected with a luciferase reporter constructs containing different 
promoters along with a Renilla luciferase expression plasmid (pRL-TK) for 
normalization. Cells were lysed in passive lysis buffer and luciferase activity was 
analyzed using a luminometer and dual luciferase assay kit according to the 
manufacturer Promega (Medical Supply, Dublin, Ireland). Transfections were 
performed in triplicate dishes and Luciferase counts (RLUs) were normalized using TK 
Renilla luciferase co-transfection. Background luminescence was subtracted, and 
Luciferase activity was expressed as fold of the increase with respect to the control.  
 
Western blot and immunoprecipitation 
Cells were lysed on a buffer containing 50 mM Tris HCl, pH 7.5, 1 mM 
phenylmethylsulfonyl fluoride, 50 mM NaF, 5 mM sodium pyrophosphate, 1 mM 
sodium orthovanadate, 0.1% Triton X-100, 1 mg/ml leupeptin, 1mM EDTA, 1 mM 
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EGTA and 10 mM sodium ȕ-glicerophosphate. 
For immunoprecipitation experiments, cells were lysed on a buffer containing 40 
mM Hepes pH 7.5, 120 mM NaCl, 1mM EDTA, 10 mM sodium pyrophosphate, 10 mM 
sodium glycerophosphate, 50 m sodium fluoride, 0.5 mM sodium orthovanadate and 
0.3% CHAPS. Briefly, lysate (1–4 mg) was pre-cleared by incubating with 5–20 µl of 
Protein G–Sepharose coupled to pre-immune IgG. The lysate extracts were then 
incubated with 5–20 µl of Protein G–Sepharose conjugated to 5–20 µg of the antibody 
or pre-immune IgG (the antibody was previously covalently coupled to Protein G–
Sepharose using dimethyl pimelimidate, from Sigma Aldrich). Immunoprecipitations 
were carried out overnight on a rotating wheel. The immunoprecipitates were washed 4 
times with lysis buffer, followed by 2 washes wit Hepes buffer (25 mM Hepes pH 7.5 
and 50mM KCl). Then the immunoprecipitates were resuspended in 30 µl of sample 
buffer (not containing 2 ȕ-mercaptoethanol), filtered through a 0.22-ȝm pore- size Spin-
X filter and 2 ȕ-mercaptoethanol was finally added to a concentration of 1% (v/v). 
Samples were subjected to electrophoresis and immunoblot analysis. Western blot 
analysis was performed following standard procedures. A list of the primary antibodies 
used is shown as a table at the end of the Supplementary methods section. 
Densitometric analysis was performed with Quantity One software (Bio-Rad; 
California, US). 
 
Cytosolic and nuclear fractionation 
Nuclear and cytosolic fractions were obtained from total cell lysates as described 
previously (10).  
 
 
Reverse transcription-PCR 
RNA was isolated by using Trizol Reagent (Invitrogen, following manufacturer´s 
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instructions) and including a DNase digestion step with the RNasefree DNase kit 
(Qiagen; Maryland, US). cDNA was subsequently obtained using the first strand cDNA 
synthesis kit (Roche) or with the Transcriptor Reverse transcriptase (Roche). Human 
TRB3 sense (5´-GCCACTGCCTCCCGTCTTG-3´) and antisense 5´-
GCTGCCTTGCCCGAGTATGA-3´) primers were used to determine the hTRIB3 
levels in tumor samples derived from U87MG, BT474 and HEPG2 shC and shTRIB3 
cells. Multi-species GAPDH sense (5´-GGGAAGCTCACTGGCATGGCCTTCC-3´) 
and antisense (5´-CATGTGGGCCATGAGGTCCACCAC-3´) primers were used to 
normalize as a control. PCR reactions were performed using the following parameters: 
95°C for 5 min, 94°C for 30 s, 52°C for 30 s, and 72°C for 1 min, followed by a final 
extension step at 72°C for 5 min. The number of cycles was adjusted to allow detection 
in the linear range. 
 
Real-time quantitative PCR 
cDNA was obtained with Transcriptor (Roche). Real-time quantitative PCR assays were 
performed using the FastStart Master Mix with Rox (Roche) and probes were obtained 
from the Universal Probe Library Set (Roche). Primer sequences and Roche´s probes 
corresponding to each pair of primers can be found in supplemental table 3. 
Amplifications were run in a 7900 HT-Fast Real-Time PCR System (Applied 
Biosystems; California, US). Each value was adjusted by using 18S RNA levels as 
reference. 
 
Cell invasion assay 
The cell invasion was monitored using cell culture matrigel invasion chambers (BD 
Biosciences, Bedford, MA). Briefly, cells were trypsinized, washed, resuspended in 
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DMEM 0.1% FBS and loaded into the insert (50 000 cells/chamber). DMEM 
supplemented with 10% FBS was placed in the plate well as a cell migration stimulus. 
Cells were allowed to migrate for 24 h at 37°C through an 8-ȝm polyethilene 
terephthalate tracketched membrane included in the matrigel invasion chambers (BD 
Biosciences). Then, cells from the upper side of the membrane were removed. The 
remaining cells on the bottom side of the membrane were fixed with 4% 
paraformaldehyde (10 min at room temperature) and stained with DAPI (Invitrogen; 10 
min, room temperature) before montage with Mowiol was performed. Fluorescence 
images were acquired using a Zeis Axioplan 2 Microscope. 
 
Soft agar colony formation assay: anchorage independent growth 
Briefly, sterilized 0.5% agar and 0.35% agar in DMEM supplemented with 10% FBS 
were melted in a microwave and cooled to 37°C in a water-bath. 1.5 ml of 0.5% agar 
complete medium was added to each well in a 6-well plate and set aside for several 
minutes to allow agar solidification. Cells were then trypsinized, washed and 
resuspended in complete medium at a final concentration of 200 000 cells/ml. One 
hundred µl of this preparation were mixed with 6 ml of 0.35% agar complete medium 
and 1.5 ml (5 000 cells) of these mixtures were carefully added to each well (over the 
base layer) and incubated at 37°C 5% CO2 for 7-28 days. The resulting colonies were 
morphologically assessed and quantified after staining with crystal violet (0.05% in 
25% methanol).  
 
In vivo generation of tumor xenografts 
Tumors were induced by subcutaneous injection in nude mice (Harlan Interfauna 
Iberica, Barcelona, Spain) of 4 x106 cells (RasV12/E1A-Trib3+/+ and Trib3-/- MEFs, 
empty vector- or FOXOA3-RasV12/E1A-transformed Trib3+/+ and Trib3-/- MEFs; shC- 
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or shTRIB3-HEPG2, BT474 and U87MG cells) in PBS supplemented with 0.1% 
glucose. Tumors were routinely measured with external caliper, and volume was 
calculated as (4p/3) x (width/2)2 x (length/2).  
 
 
Confocal microscopy and Immunofluorescence of cells and tumor samples 
Cell cultures grown on 12 mm-coverslips were washed in PBS, fixed with 4% 
paraformaldehyde (20 min at room temperature), permeabilized with 0.5% Triton X-100 
(5 min at room temperature), incubated with the corresponding primary antibodies (for a 
detailed list of the antibodies used in immunofluorescence experiments, see  table at the 
end of the Supplementary Methods section), washed and incubated with Alexa-488 or 
Alexa- 594-conjugated secondary antibodies (Invitrogen; Carlsbad, California, US) in 
the dark at room temperature for 1 h. Cell nuclei were stained with Hoechst 33342 
(Invitrogen). Finally, coverslips were mounted in ProLong Gold antifade reagent 
(Invitrogen) and visualized in a Leica TCS SP2 confocal microscope.  
Samples from tumor xenografts were dissected, Tissue-Tek (Sakura; South 
Carolina, US) embedded and, before the staining procedures were performed, fixed in 
acetone for 10 min at room temperature and frozen. After fixation, sections (5 ȝm) were 
permeabilized and blocked to avoid non-specific binding with 10% goat antiserum and 
0,25% Triton X-100 in PBS for 45 min and subsequently incubated with the primary 
antibodies shown in Supplemental table 2. Then, samples were washed, incubated with 
the corresponding Alexa-488 or Alexa-594-conjugated secondary antibodies 
(Invitrogen; 90 min, room temperature) and nuclei were stained with DAPI (Invitrogen; 
10 min, room temperature) before montage with Mowiol mounting medium (Merck, 
Darmstadt, Germany) was performed. Fluorescence images were acquired using 
Metamorph-Offline 6.2 software (Universal Imaging) and Zeiss Axioplan 2 
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Microscope. 
 
Immunohistochemistry 
Paraffin-embedded sections from tumors were deparaffinized and rehydrated using 
standard protocols and subjected to heat-induced antigen retrieval in citrate buffer. 
Endogenous peroxidase blockade and unspecific binding reduction were achieved by 
successive incubation with 3% H2O2 and 5% goat serum (Abcam) supplemented with 
3% BSA and 1% Triton X-100 (Sigma), respectively. Samples were then incubated with 
an anti-pAKTSer473  antibody (1/100), an anti-pFOXO antibody (1/100) or an anti-
PCNA antibody (1/400) and further processed with appropriate secondary antibodies 
following the LSAB2 horseradish peroxidase kit’s instructions (Dako cytomation, 
Carpenteria, CA). Hematoxilin were used for nuclei staining.  Images were acquired 
with Cell^A software (Olympus, Münster, Germany) 
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List of antibodies used in Western blot analyses 
 
Antigen Host Company 
TRB3 Nt rabbit Abcam, Cambridge, UK 
Phospho-Akt (Ser473) rabbit Cell Signaling 
Phospho-Akt (Thr308) rabbit Cell Signaling 
Total Akt sheep Kindly donated by Dr. Dario Alessi 
Phospho-FoxO1 (Thr24)/FoxO3a 
(Thr32) 
rabbit Cell Signaling 
Total FoxO3a rabbit Cell Signaling 
Phospho-Bad (Ser136) mouse Cell Signaling 
Total Bad rabbit Cell Signaling 
phospho-PRAS40 (Thr246) sheep Kindly donated by Dr. Dario Alessi 
Total PRAS40 sheep Kindly donated by Dr. Dario Alessi 
Phospho-GSK3 ҏҞSer 9) rabbit Cell Signaling 
Total GSK3  rabbit Cell Signaling 
phospho-S6 ribosomal protein (Ser 
235/236) 
rabbit Cell Signaling 
Total S6 ribosomal protein mouse Cell Signaling 
Cleaved caspase 3 (Asp175) rabbit Cell Signaling 
HA rat Santa Cruz Technology 
Lamin A/C rabbit Cell Signaling 
IKBĮ rabbit Santa Cruz Biotechnology 
ȕactin mouse Sigma Aldrich 
Įҟtubulin mouse Sigma Aldrich 
 
List of antibodies used in immunofluorescence or immunohistochemistry 
analyses 
Antigen Host Company 
Cleaved caspase 3 (Asp175) rabbit Cell Signaling 
Ki67 rabbit Neomarkers 
Phospho-Akt (Ser473) rabbit Cell Signaling 
Phospho-FoxO1 (Thr24)/FoxO3a 
(Thr32) 
rabbit Cell Signaling 
Total FoxO3a rabbit Cell Signaling 
PCNA mouse Abcam 
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List of primers used in quantitative PCR analyses  
Gene Specie Primers Probe 
TRB3 mouse CGCTTTGTCTTCAGCAACTG 
TCATCACGCAGGCATCTTC 
67 
RICTOR mouse AGTGAATCTGTGCCATCGAGT 
AAGGAAAAATGTGCTAGTAGAGCTG 
88 
FOXO3a mouse CTTCAAGGATAAGGGCGACA 
GACAGATTGTGGCGAATTGA 
11 
Rho GTPase- 
activating protein 
mouse TGGCTCCAGCAGAGGAAG 
CATGCTGTTCCAGGTGAAGTC 
75 
Fibroblast Growth 
Factor  13 
mouse AGGCAGATGGAACCATTGAT 
CCCACAGGGATGAGGTTAAA 
56 
Annexin A1 mouse GTGAACGTCTTCACCACAATTC 
GTACTTTCCGTAATTCTGAAACACTCT 
18 
NDRG1 mouse TTCATCAGCGCCTACAACAG 
AGTGTGGGTTCCAGGCATT 
80 
Protocadherin 17 mouse GCCACTCGGATGTCCATAAT 
GGGTCCTTAAACGTGGAGCTA 
27 
Tumor necrosis factor 
receptor 
mouse GGAAAGTATGTCCATTCTAAGAACAA 
AGTCACTCACCAAGTAGGTTCCTT 
84 
Neuropilin 1 mouse CCACACACAGTGGGCTTG 
GGTCCAGCTGTAGGTGCTTC 
26 
Fibronectin 1 mouse CGGAGAGAGTGCCCCTACTA 
CGATATTGGTGAATCGCAGA 
52 
Growth factor 
receptor Bound 
protein 7 (Grb7) 
mouse GTCCGGCTCCTTCTGTTG 
GGGAGCTGCTGAGATGAGTC 
1 
Neural cell adhesion 
molecule 1 (NCAM1) 
mouse AGGGCAAGGCTGCTTTCT 
CCCCATCATGGTTTGGAGT 
69 
Endophilin mouse CCGCCCTGAAGGAGATAAC 
CTCAATTCCTGTTCAGATTTTGTC 
6 
Sortilin 1 mouse CGGATATCACGACGACTCAG 
GAGCCTCAGGGAGTGTAGGA 
17 
Smad 5 mouse GCAGTAACATGATTCCTCAGACC 
GCGACAGGCTGAACATCTC 
107 
16 
 
BIM mouse GGAGACGAGTTCAACGAAACTT 
AACAGTTGTAAGATAACCATTTGAGG 
41 
18S RNA multi-
species 
GCTCTAGAATTACCACAGTTATCCAA 
AAATCAGTTATGGTTCCTTTGGTC 
55 
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